Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Celgene takes option on Triphase WDR5 compound
by Lisa Jarvis
February 1, 2019
| A version of this story appeared in
Volume 97, Issue 5
Celgene will pay $40 million up front for an option to acquire Triphase Accelerator’s small molecule targeting WDR5 protein, a key player in the formation of protein complexes that indirectly modify genes. Leukemia and other blood cancers can arise due to the misregulation of WDR5-associated protein complexes. The deal for the preclinical compound is Celgene’s third cancer pact since Bristol-Myers Squibb announced it would buy the New Jersey–based company for $74 billion last month.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter